Dogwood Therapeutics Inc
dwtx.comWhat Do They Do?
Develops medicines for patients with cancer-related pain and neuropathy, including non-opioid candidates for chemotherapy-related pain and nerve damage.
10-K for FY2025, filed Mar 18, 2026We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy.…View ↗
Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Nav1.7 modulation program is intended to treat…View ↗
SP16 is a synthetic anti-inflammatory peptide developed to replicate the cytoprotective and anti-inflammatory signaling properties of…View ↗
The SP16 program is in early Phase 1 development with a National Cancer Institute funded grant and is expected to start in mid-2026. The…View ↗
How Do They Make Money?
No revenue reported yet.
10-K for FY2025, filed Mar 18, 2026
Who Are Their Customers?
If its candidates receive approval, Dogwood plans to use sales and marketing agreements with pharmaceutical companies to reach anesthesiologists, oncologists and primary care physicians.
How Are They Changing?
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 14, 2026
−$11.5MView ↗
- ▲ +203% (Loss)
- vs −$3.8M in Q2 FY2025
-
Aug 13, 2026
Dogwood announced a development and commercialization partnership for legacy antiviral assets
The partnership could provide value up to $100M to Dogwood Therapeutics and its CVR holders.
Sources
8-K, filed Aug 13, 2026
- Announced Worldwide Development and Commercialization Partnership for Legacy Antiviral Assets with potential value up to $100M to Dogwood…View ↗
Pipeline focus
The earlier report centered on antiviral therapies for fibromyalgia, led by a combination candidate; the latest report centers on pain and neuropathy medicines, while describing antiviral programs as partnership opportunities.
10-K for FY2022, filed Mar 14, 2023 10-K for FY2025, filed Mar 18, 2026We are a development-stage biotechnology company focused on advancing novel antiviral therapies to treat diseases associated with a viral…View ↗
We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and neuropathy.…View ↗
Our pipeline is focused on treating chronic neuropathic pain and neuropathy. Our Halneuron® Nav1.7 modulation program is intended to treat…View ↗
While our primary focus is on advancing development of Halneuron® and SP16, we continue to explore partnership opportunities to advance our…View ↗
Loading...
